756 / 1138
Conclusions
•
Keeping up with changes in developments in diagnosis, staging
and follow-up of early-stage NSCLC is essential in order to
influence members of your MDT.
•
We need improvements in treatment workflow, including non-
invasive volumetric imaging.
•
Be critical when evaluating ‘new’ developments as late
recurrences are possible.
•
Ensure continuous training and education for all members of
your tumor board MDT.